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Abstract
Ubiquitin proteasome system (UPS) is an emerging arena in cancer intervention. 
Dysregulation of various UPS components has been implicated with many cancers, and 
this knowledge is starting to be exploited for its role in cancer initiation, progression, and 
therapeutics. UPS regulates both protein turnover and non-proteolytic regulatory func-
tion of the proteins involved in cell cycle, signal transduction, DNA repair, histone modi-
fication, and transcription. In addition, chromosomal aberrations and genomic alterations 
often present in the cancer cell genomes lead to excess of conformationally challenged 
aggregation-prone proteins and proteotoxic stress that make cancer cells more depen-
dent on UPS-mediated protein degradation than normal cells. This proposition is the 
basis of the clinical use of proteasome inhibitor, Bortezomib, to treat multiple myeloma 
and mantle cell lymphoma targeting cancer cells and mostly sparing the normal cells. 
This chapter provides an overview of various components of UPS which are implicated 
in cancer and regulate ubiquitin-mediated oncogenic signaling in ovarian cancer.
Keywords: ovarian cancer, mutant p53, ubiquitin, proteasomes, deubiquitinating 
enzymes
1. Introduction
Ovarian cancer is the most lethal gynecologic malignancy with a high case-to-fatality ratio 
[1]. According to American Cancer Society, approximately 22,440 new cases of ovarian can-
cer will be diagnosed in the year 2017 and about 14,080 women in the United States will die 
from this deadly disease [2]. About 90% of ovarian carcinomas are heterogeneous epithelial 
neoplasms with distinctive biology and clinicopathologic features at cellular and molecular 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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levels [1, 3]. The clinical management of ovarian cancer has addressed this heterogeneity and 
classified ovarian cancer into high-grade and low-grade serous, endometrioid, clear cell, and 
mucinous subtypes based on the histology, tissue of origin, prognosis, and genetic alterations 
that deregulate specific signaling pathways in these tumor cells [4, 5] (Figure 1). Of these, 
high-grade serous ovarian cancer (HGSOC) is the most prevalent and lethal subtype of ovar-
ian cancer. It accounts for 70–80% of ovarian cancer deaths [1]. The low five-year survival rate of 
HGSOC patients is attributed to the late detection of extensively metastasized disease, espe-
cially to omentum, which is the primary site of ovarian cancer metastasis. Moreover, about 
80–90% of HGSOC patients eventually develop chemo-resistant tumors, after an initial posi-
tive response to cytoreductive surgery and chemotherapy, which are important prognostica-
tors of the survival of HGSOC patients [1, 3]. The initiation and development of HGSOC is 
known to proceed through the early acquisition of genetic alterations in the tumor suppressor 
gene TP53 [3, 6]. About 96% of HGSOC patients carry gain-of-function (GOF) mutations in 
TP53 gene [3]. It is believed that TP53 mutations lead to the precursor lesions in fallopian tube 
fimbria, which develop into serous tubal intraepithelial carcinoma (STIC) and ultimately to 
HGSOC [7, 8]. The reduced risk of ovarian cancer in BRCA1 mutation carriers after salpingo-
oophorectomy supports the theory of HGSOC origin from STIC [9]. Mutant p53 orchestrates 
a distinct pro-tumorigenic signaling network and confer chemo-resistance through transcrip-
tion-dependent and independent mechanisms in cancer cells. A recent study in triple-negative 
breast cancer cells revealed the role of mutant p53-proteasome axis in regulating global effects 
on cancer cell’s protein homeostasis, inhibiting tumor suppressive pathways or turning on 
the oncogenic signaling in cancer cells [10]. A growing number of evidences suggest the role 
of ubiquitin signaling in tumor progression and growth. This chapter discusses the role of 
ubiquitin-mediated signaling in ovarian cancer pathogenesis. The different components of 
ubiquitin proteasome system, which are involved in this regulation, will be highlighted.
Figure 1. A schematic representation of molecular drivers of low- and high-grade ovarian cancer initiation and 
progression. Low-grade tumors are low malignant potential (LMP) tumors associated with KRAS or BRAF mutation 
and loss of PTEN. High-grade serous tumors frequently have mutated TP53 gene as well as activated members of PI3K/
Akt pathway. Highly invasive tumors originate from the fallopian tube precursor lesion, STIC, and spread to the ovary 
and other peritoneal surfaces. Genotoxic stresses in BRCA1/2 carriers predispose them to ovarian cancer.
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1.1. Conceptual overview of ubiquitin modifications
Protein ubiquitination is a dynamic multifaceted posttranslational modification (PTM), which 
is involved in nearly all biological functions in a eukaryotic cell. Similar to phosphorylation, 
it functions as a signaling device and can be activated by extracellular stimuli, DNA damage, 
phosphorylation, ligand-dependent receptor activation, and signal transduction. Ubiquitin is 
a highly conserved 76-amino acid protein, which is expressed in all cell types. It has seven 
lysine (Lys or K) residues, K6, K11, K27, K29, K33, K48, and K63. Each lysine residue can 
result in a linkage-specific ubiquitin chain of certain topology [11, 12], which when bound to 
the target protein (substrate) dictates the fate of the protein (Figure 2). For example, the most 
predominant K48-linked polyubiquitin chains, which have a compact conformation, lead to 
the proteasomal degradation of the bound substrate. By contrast, the second most abundant 
K63-linked chains, which have an open conformation, are involved in non-proteolytic regula-
tory functions [13]. The K11-linked ubiquitin chains act as an additional proteasomal degra-
dation signal, particularly in cell-cycle regulation [13]. The functions of the other lysine-specific 
ubiquitin chains remain less well characterized. K6-linked chains are shown to be upregu-
lated with UV genotoxic stress and are known to be associated with BRCA1/BARD1 complex 
[14]. Similarly, K27 chains act to serve as scaffolds for protein recruitment such as p53-binding 
protein 1 in the DNA damage response. In addition, ubiquitin chain of mixed topology with 
different linkage at succeeding positions is also seen as in NF-κB signaling or in protein traf-
ficking (Figure 2F) [13]. Moreover, branched ubiquitin chains of unknown function are gener-
ated when a single ubiquitin is modified with multiple molecules [12, 13]. These ubiquitin 
chains creating a multitude of signals with distinct cellular outcomes are referred to as “ubiq-
uitin code” [13]. New layers of the ubiquitin code are emerging, based on findings that 
revealed the modification of ubiquitin chains with small ubiquitin-like (Ubl) modifier such as 
SUMO, phosphorylation, and acetylation [13].
Ubiquitination is an orchestrated enzymatic reaction of E1 ubiquitin-activating enzyme, E2 
ubiquitin-conjugating enzyme, and ubiquitin E3 ligase (E3). It is the most coordinated and con-
served multistep process of covalently tagging a protein with mono- or polyubiquitin chain. 
The process begins with the ATP-dependent activation of ubiquitin by E1 ubiquitin-activating 
enzyme (E1s), which then transfers it to the active site cysteine of E2 ubiquitin-conjugating 
enzymes (E2s) forming a thioester linkage between ubiquitin and cysteine. Ubiquitin E3 ligases 
(E3s) have a central role in this process, as they recognize the specific protein substrates and 
facilitate the transfer of ubiquitin from the E2 onto the target protein [11, 12]. Deubiquitinating 
Box 1. The discovery of ubiquitin-mediated protein degradation in the late 1970s by Drs. Avram Hershko, Aaron 
Ciechanover, and Irwin Rose was awarded 2004 Nobel Prize in Chemistry. Their study highlighted the role of pro-
tein ubiquitination in selective protein breakdown, regulating the cellular functions by modulating the levels of key 
enzymes, regulatory proteins and removal of abnormal proteins that arise by biosynthetic errors or post synthetic 
damages. Ubiquitin was first isolated from bovine thymus in 1975 by Goldstein et al. (PNAS, 1975;72:11-15) [88] and 
found to be covalently attached to histone 2A (Goldknopf and Busch, PNAS, 1977;74:864-868) [89]. Subsequently, Drs. 
Hershko, Ciechanover, and Rose in a series of biochemical studies discovered and characterized the ATP-dependent, 
ubiquitin-mediated protein degradation using the reticulocyte lysate system (PNAS, 1979;76:3107-3110) [90].
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enzymes (DUBs) are another class of enzymes, which removes or edits the ubiquitin chains 
attached to a protein, making this a highly reversible process and thus highlighting the dynamic 
regulation of ubiquitin signaling in the cell (Figure 3). These enzymes together with protea-
somes, a cellular machinery involved in ubiquitin-mediated protein degradation,  comprise the 
Figure 3. Enzymatic cascade of ubiquitin proteasome system. Ubiquitin is activated and conjugated to target protein by 
a conserved action of E1-ubiquitin-activating enzyme, E2-ubiquitin-conjugating enzyme, and E3 ubiquitin ligase.
Figure 2. Linkage-specific ubiquitin chains of different topologies. Each circle represents one ubiquitin moiety. (A) 
Monoubiquitination, (B) multi-monoubiquitination, (C) K48-linked chain, (D) K63-linked chain, (E) branched chain, and 
(F) mixed chain.
Ovarian Cancer - From Pathogenesis to Treatment138
ubiquitin proteasome system (UPS). UPS plays an indispensable role in regulating ubiquitin-
mediated proteolytic and non-proteolytic regulatory signaling to control cellular homeostasis, 
protein stability, and a wide range of signaling pathways.
2. UPS components in ovarian cancer
Ovarian cancer is characterized by multiple genetic and epigenetic abnormalities and several 
major (about seven) activated signaling pathways, which are directly or indirectly implicated 
with UPS. Moreover, several UPS components, E1s, E2s, E3s, DUBs and proteasomes are known 
to be deregulated or mutated in cancer (Table 1), suggesting their role in cancer signaling and 
cancer progression. This section discusses each UPS component implicated in ovarian cancer 
and the role of key players of each component in regulating ovarian cancer signaling (Figure 4).
2.1. E3 ligases
E3 ligases (E3s) are the most heterogeneous class of enzymes in UPS as they facilitate ubiq-
uitination with exquisite spatial, temporal, and substrate specificity. There are more than 600 
E3s in a human genome, indicating the precise substrate specificity of E3s [15]. E3s can be 
classified into three main types, RING E3s, HECT E3s, and RBR E3s depending on the pres-
ence of type-specific domains and on the mechanism of ubiquitin transfer to the substrate 
protein. RING E3s are the most abundant type of ubiquitin ligases. They are characterized by 
the presence of zinc-binding domain called Really Interesting New Gene (RING) and U-box 
domain. RING E3s mediate a direct transfer of ubiquitin to substrate, functioning as a scaf-
fold to orient the ubiquitin-charged E2, whereas E3s with homologous to the E6AP carboxyl 
Gene. Role Effect Cancer [references]
BRCA1 E3 ligase Mutation, loss of tumor suppressor 
function
Ovarian and breast cancers [19, 20]
USP13 DUB Amplification, oncogene Ovarian cancer [41]
Mdm2 E3 ligase Overexpression, loss of p53 tumor 
suppressor function
Ovarian cancer and various malignancies [63, 64]
USP7 DUB Overexpression, oncogene Ovarian cancer [42]
Skp2 E3 ligase Overexpression, loss of tumor 
suppressor function of p27
Ovarian, breast, and prostate cancers [76–81]
UCHL1 DUB Overexpression or methylation, role 
varies with cancer
Ovarian, breast, gastric, lymphoma, lung, 
Esophageal squamous cell carcinoma [44–48]
FBW7 E3 ligase Mutation, loss of tumor suppressor 
function
Ovarian and endometrial cancer, leukemia [71]
VHL E3 ligase Mutation, loss of tumor suppressor 
function
Clear-cell carcinoma, lung cancer [49]
Table 1. Cancer-associated alterations in UPS.
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terminus (HECT) domain transfer ubiquitin to the substrate in a two-step process—ubiquitin 
is first transferred to a catalytic cysteine on E3 and then to the substrate. Based on their N ter-
minus extensions, HECTs are further classified into three subfamilies: Nedd4 family, HERC 
family, and other HECT that contain various domains. The RBR E3s are characterized by the 
presence of three RING domains, RING1 and RING2, separated by an in-between-RING (IBR) 
domain. RING1 recruits the ubiquitin-charged E2, RING2 possess catalytic cysteine. The IBR 
is called benign-catalytic domain as it lacks catalytic cysteine residue [15]. Given their cellular 
specificity and complexity, E3s are implicated in a number of pathophysiological conditions, 
which makes them an attractive therapeutic target in human diseases, including cancer [16].
2.1.1. BRCA1
The breast and ovarian cancer susceptibility gene, BRCA1, is a tumor suppressor gene [17]. 
Heterozygous mutations in BRCA1 gene predispose women to both familial and sporadic 
breast and ovarian cancers [18, 19]. Nonetheless, BRCA1 mutations are also associated with 
other cancers like stomach, pancreas, prostate, and colon [20]. BRCA1 acts as a hub protein, 
which participates in several different protein complexes to coordinate a diverse range of cel-
lular functions including DNA repair, cell-cycle regulation, apoptosis, transcriptional regula-
tion, and centrosome duplication to maintain genomic stability [17]. The structural analysis of 
BRCA1 protein suggested that it has a RING finger domain that harbors E3 ubiquitin ligase 
activity [14]. In addition, BRCA1 forms a heterodimer complex with BARD1, a protein with 
a RING finger domain [14]. BARD1 interaction stabilizes the proper conformation of BRCA1 
Figure 4. Key players of each UPS component involved in regulating ovarian cancer signaling. (A and B) DUBs and E3 
ligases as candidate genes in ovarian cancer, (C) proteasomal activity and inhibitors in ovarian cancer, and (D) regulation 
of ovarian cancer oncogenic signaling by UPS.
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RING domain for a potent E3 ligase activity and interaction with E2 UbcH5 [14, 21, 22]. 
BRCA1 E3 ligase substrate specificity is believed to depend on its phosphorylation-depen-
dent binding to proteins containing phospho-SXXF motif such as CtIP, BACH1, and ABRA1 
through a phospho-peptide recognition domain (BRCT) [23, 24]. The strong relation between 
BRCA1 tumor suppressor properties and E3 ligase activity is evident from the clustering of 
missense mutations that predispose to cancer in the Zn2+-binding residues of BRCA1 RING 
finger domain crucial for its ubiquitin ligase activity [25]. The full range of function of BRCA1/
BARD1 complex is not completely understood [18]. One of the most important functions of 
BRCA1 is to repair DNA double-strand breaks (DSBs). Following DNA damage, chromatin-
associated histone H2AX phosphorylation by ATM and ATR at DNA damage site recruits an 
E3 ubiquitin ligase RFN8 and a phospho-module-binding mediator MDC1 at the damage site 
[17, 26–28]. RFN8 together with ubiquitin conjugase Ubc13, ubiquitinate histone H2A and 
H2B at chromatin lesions, which in turn translocate BRCA1 complex containing RAP80, a 
protein with ubiquitin-interacting motif (UIM), ABRA1, protein that interacts with BRCA1 
BRCT domain and deubiquitinating enzyme, BRCC36 to Lys6- and Lys63-linked polyubiq-
uitin chains at DSBs [17, 26, 29]. BRCA1 has also been implicated with the transcriptional 
activation of genes in response to DNA damage. The C-terminus of BRCA1 complexes with 
RNA polymerase II through RNA helicase, while N-terminus BRCA1/BRAD1 heterodimer 
binds to RNA polymerase II holoenzyme [30]. Identifying genes regulated by BRCA1 would 
shed a significant light on the transcriptional role of BRCA1. However, BRCA1 overexpres-
sion studies have shown induction in p53-responsive E3 ligase, mdm2, cell-cycle inhibitor, 
p21 and stress-response factor, and GADD45 in breast and small-cell lung cancer cell lines [31, 
32]. Besides, BRCA1 also regulates G1/S, S-phase, and G2/M cell-cycle checkpoints through 
interactions with RAD3, ATM/ATR, and Chk1/Chk2 [26, 30, 33].
Over the last 10 years, significant information has been gained about the structure, function, 
and unique features of BRCA gene products, BRCA1 and BRCA2, which collectively contrib-
utes to the biological response to DNA damage through homologous recombination of DNA 
repair and regulation of cell-cycle checkpoints. BRCA1/2-deficient cancers, including ovarian 
cancer, are now recognized as the target for a class of drugs known as PARP (poly ADP-
ribose polymerase) inhibitors [34]. PARP detects and initiates an immediate cellular response 
to metabolic or radiation-induced single-strand DNA breaks (SSB). It binds to DNA and syn-
thesizes polymeric adenosine diphosphate ribose (poly ADP-ribose or PAR), which acts as 
signal to other DNA-repairing enzymes. PARP inhibition directly blocks the PARP enzymatic 
activity and subsequently leads to PARP accumulation on DNA, a process called PARP trap-
ping, which converts an SSB into a double-strand DNA break through the collapse of replica-
tion fork [34]. BRCA-deficient tumor cells with impaired homologous recombination repair of 
double-strand DNA breaks are directed toward the error-prone repair process of non-homol-
ogous end joining which leads to genetic instability and cell death. Thus, BRCA1/2-deficient 
ovarian cancer cells with PARP inhibition undergo synthetically lethal cell death [34]. PARP 
inhibitor, Olaparib manufactured by AstraZeneca, is in phase I/II clinical trials for BRCA-
deficient high-grade serous ovarian cancer [34]. Olaparib-treated ovarian cancer patients with 
BRCA1/2 mutation had a progression-free survival of 11.2 months compared to 4.3 months of 
patients receiving placebo [35]. In summary, BRCA is an ideal example of E3 ubiquitin ligase 
playing an essential role in ovarian cancer and its intervention.
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2.1.2. Cullin-RING ligases: cullin 4
Cullin-RING ubiquitin ligases (CRLs), composed of CUL1, 2, 3, 4A, 4B, 5, and 7, are the larg-
est family of E3s that ubiquitinate a wide array of substrates involved in cell-cycle, DNA-
damage response, chromatin remodeling, and gene expression. Cullin (CUL) neddylation, a 
process of adding ubiquitin-like protein—NEDD8 to the cullin [36], is crucial for their activa-
tion. Neddylation is catalyzed by NEDD8-activating enzyme E1 (NAE), NEDD8-conjugating 
enzyme E2 (UBC12), and NEDD8-E3 ligase. The genome-wide analysis of human cancers 
revealed CUL4A amplification in 20% of the basal-like breast cancer subtype, characterized as 
“triple negative,” and CUL4A levels were associated with aggressive growth and poor prog-
nosis. Dysregulation of CUL4A in multiple tumor types leads to the hypothesis that CUL4A 
plays a role in promoting oncogenesis [36]. High CUL4A expression and activity in ovarian 
cancer is implicated with cancer cell proliferation and survival. NEDD8-activating enzyme 
inhibitor, MLN4924, which blocks cullin neddylation activation, is reported to induce cell-
cycle arrest, apoptosis, and tumor cell growth in epithelial ovarian cancer cells. In addition, 
MLN4924 sensitized ovarian cancer cells to chemotherapeutic drug treatments [37].
The role of Skp2 and FBXW7 in ovarian cancer signaling is discussed in the next section.
2.2. Deubiquitinating enzymes
Reversibility is an important aspect of ubiquitin system, which is mediated by deubiquitinat-
ing enzymes or deubiquitinases (DUBs). DUBs are essential components of UPS that possess 
ubiquitin-isopeptidase activity and catalyze the removal of ubiquitin from the target proteins. 
Thus, DUBs play a crucial role in the regulation of ubiquitin-mediated regulatory and proteo-
lytic signaling [11, 38]. DUBs activity affect the activation, recycling, localization, and turn-
over of multiple proteins, which in turn regulate cellular homeostasis, protein stability, and 
a wide range of signaling pathways [39]. DUBs also maintain ubiquitin homeostasis in the 
cell by generating free ubiquitin monomers, which is essential for ubiquitin-mediated regula-
tion of cell function [38]. Consistent with this, an altered DUB expression or activity has been 
implicated with several diseases including cancer. Numerous DUBs have been characterized 
as oncogenes mediating cancer initiation and progression [11, 40]. Therefore, pharmacologi-
cal interventions targeting DUB activity using small molecule inhibitors are being used as a 
rationale to search for novel anticancer drugs [11].
DUBs role is evident in several cancers including Fanconi anemia (USP1), prostate can-
cer (USP2), adenocarcinoma (USP4), non-small-cell lung carcinoma (USP7), glioblastoma 
(USP15), myeloma, and leukemia (USP9x) [11, 39]. Han et al. identified the role of USP13 as 
Box 2. About 98 DUBs are reported in human genome, which are mainly divided into five families based on their 
sequence and structural homology: Ubiquitin-specific protease (USP), ubiquitin carboxyl-terminal hydrolases 
(UCHs), ovarian tumor proteases (OTUs), Machado Joseph disease proteases (MJD), and JAB1/MPN/Mov34 (JAMM) 
metallopeptidases. Most DUBs are cysteine proteases except JAMMs, which belong to catalytic class of metallopro-
teases. The recent discovery of DUBs with the selectivity of cleaving extended Lys-48-linked polyubiquitin chains 
belongs to new family of DUBs named Mindy. The DUB-substrate specificity somewhat depends on ubiquitin chain 
linkage and topology; however, by large, given the complexity of ubiquitin system, it remains unknown [38].
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the master regulator of ovarian cancer metabolism [41]. They reported the co-amplification 
of USP13 gene with PIK3CA (phosphatidylinositol-3-kinase catalytic subunit, α-isoform) in 
29.3% of high-grade serous ovarian cancer patients and its association with poor clinical out-
come. USP13 stabilized the protein levels of two key metabolic enzymes, ATP citrate lyase and 
oxoglutarate dehydrogenase, which in turn regulate the mitochondrial respiration, glutami-
nolysis, and fatty acid synthesis in ovarian cancer cells. USP13 inhibition suppressed ovarian 
tumor progression and sensitized the tumor cells to PI3K/AKT inhibitor [41]. Similarly, USP7 
(also known as HAUSP, herpes virus-associated ubiquitin protease) plays a crucial role in 
ovarian cancer [42]. USP7 is a DUB for MDM2, which prevents MDM2 autoubiquitination, 
leading to its stabilization and consequent induction of p53 degradation. Treating an ovarian 
cancer xenograft model with a novel inhibitor of USP7, CDDO-Me suppressed tumor growth. 
CDDO-Me directly binds to USP7, which leads to a decrease in its substrate Mdm2, Mdmx 
protein levels [42]. USP4 overexpression is reported in invasive breast carcinoma, enhancing 
TGFβ signaling by stabilizing SMAD2/SMAD4 complex but not much is known about its 
role in ovarian cancer [11]. USP36 expression is increased in ovarian cancer cells compared 
to normal ovarian surface epithelium; however, further studies are needed to understand its 
role in ovarian cancer [43]. DUB UCHL1 (ubiquitin-carboxyl terminal hydrolase 1) plays a 
contradicting role in different cancers [11]; it is reported as a methylated tumor suppressor 
gene in ovarian cancer [44, 45], while it is overexpressed in lymphoma, esophageal squamous 
cell carcinoma, renal, lung cancers, and acts as an oncogene [46–48]. Under hypoxic condi-
tions, UCHL1 is shown to deubiquitinate and stabilize HIF-1α and promote tumor metastasis 
[49, 50]. We for the first time identified the oncogenic overexpression of UCHL1 in high-grade 
serous ovarian cancer and association with poor clinical outcome (unpublished data). These 
studies suggest the emerging role of DUBs in ovarian cancer and the potential of DUB inhibi-
tors in neo-adjuvant therapies for ovarian cancer.
2.3. Proteasomes
The efficient and selective degradation of cellular proteins is essential for protein qual-
ity control and maintenance of cellular homeostasis [51]. Impaired protein quality control 
and degradation is associated with many human diseases such as cancer, cardiovascu-
lar diseases, and aging-related pathophysiological conditions such as Alzheimer’s and 
Parkinson’s. UPS mediates targeted protein degradation under both normal and malignant 
conditions [52]. However, cancer cells are more dependent on UPS-mediated degradation 
to promote the degradation of tumor suppressors and various cell-cycle checkpoint pro-
teins as well as to reduce proteotoxic stress accumulated due to genomic aberrations [53]. 
The 26S proteasome is a multi-subunit complex that contains one barrel-shaped 20S cata-
lytic core particle (CP) and 19S regulatory particle (RP) that binds to one or both the ends 
of barrel-shaped CP. The active degradation of proteins is regulated by 20S CP harboring 
proteolytic active sites while 19S RP regulates substrate binding and target protein entry 
into 20S [52].
The amazing efficacy and clinical use of proteasome inhibitor Bortezomib (PS-341, Velcade) 
for the treatment of multiple myeloma and mantle cell lymphoma has encouraged research-
ers to explore the possibility of targeting other components of the UPS for cancer treatment 
[54]. However, Bortezomib has not demonstrated a significant activity against other solid 
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tumors [55]. This conundrum has spurred the development of next-generation proteasome 
inhibitors, including MLN9708 (Millennium Pharmaceuticals), Carfilzomib and ONX0912 
(Onyx Pharmaceuticals, South San Francisco, CA), and CEP18770 (Cephalon, Frazer, PA) 
[56]. Although these compounds target the same 20S CP, they differ in targeted active site 
and enzyme kinetics, resulting in activity differences based on tumor type and tumor loca-
tion. Bazzaro et al. reported elevated levels of ubiquitinated proteins and 19S and 20S pro-
teasome subunits in both low-grade and high-grade ovarian carcinoma tissues and cell lines 
compared to benign ovarian tumors and immortalized normal ovarian surface epithelium 
controls. They reported an increased sensitivity to apoptosis in proteasome inhibitor, PS-341 
treated cells, and a reduced growth of ES-2 ovarian carcinoma xenograft in immunodeficient 
mice [57]. In a similar study, proteasome inhibitor, MG132—a peptide aldehyde—showed an 
enhanced sensitivity of ovarian cancer cells, SKOV3 to cisplatin both in vitro and in vivo [58]. 
The effect of Bortezomib on ovarian cancer cells is also supported by the increased sensitivity 
of Bortezomib-treated chemoresistant ovarian cancer cells to TRAIL-induced apoptosis [59]. 
Together, these results indicate the essential role of proteasomes in mediating prosurvival 
signaling in cancer, which may also be due to altered proteasome composition resulting in an 
enhanced proteasomal activity [52].
3. UPS in ovarian cancer cellular signaling
Several important factors that are implicated in the molecular pathogenesis of ovarian cancer 
are known to be regulated by UPS, highlighting its significance in disease progression. Some 
of these factors are discussed subsequently.
3.1. Tumor suppressor p53 and Mdm2
Tumor suppressor protein p53 is a multifunctional sequence-specific transcription factor that 
plays a key role in cellular stress response. Abrogating p53 function is a key event in human 
cancers, leading to the deregulation of cell cycle, genetic instability, resistance to stress sig-
nals, and resulting in cancer development [60]. Due to its growth inhibitory properties, p53 
is maintained at low levels in the normal cells. The E3 ubiquitin ligase Mdm2 promotes p53 
ubiquitination and subsequent proteasomal degradation [61]. In addition, E4 ubiquitin ligase 
p300/CBP promotes polyubiquitination of p53 to accelerate its degradation by proteasomes 
[61]. Although Mdm2 is the predominant E3 ligase for p53, several other E3 ligases have 
been identified that can promote the degradation of p53, including C-terminus of HSP70-
interacting protein (CHIP), murine double minute 4 (MdmX), and p53-induced protein with a 
RING H2 domain (Pirh2) [60]. In addition to proteolytic ubiquitination, p53 mono-ubiquitina-
tion mediates p53 nuclear export and activity [62]. Thus, UPS plays a crucial role in maintain-
ing and regulating p53 functions.
Several cancers, including invasive breast cancer, pediatric rhabdomyosarcoma, and soft-tis-
sue sarcoma, exploit Mdm2-p53 pathway to maintain low p53 levels under genotoxic or oxida-
tive-stressed environment of cancer cell. Thus, Mdm2 gene amplification and  overexpression 
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have been reported in many cancers [63]. In addition, the expression and activity of Usp7, a 
deubiquitinating enzyme for Mdm2, is increased in several cancers including breast and ovar-
ian cancer, which prevents Mdm2 ubiquitination and promotes its stability. Reduced tumor 
growth was seen in an ovarian cancer xenograft model treated with Usp7 inhibitor [42]. On 
the other hand, when p53 acquires gain-of-function (GOF) mutations as in the case of nearly 
half of the cancers, it gains oncogenic functions and loses its wild-type tumor suppressor 
properties. Thus, in these cancer cells, several mechanisms stabilize mutant p53 through its 
activation or by inhibition of its degradation by disrupting Mdm2 and mutant p53 binding. 
Several splice variants of Mdm2 are reported in cancer, which lack a p53-binding domain and 
thus stabilizes mutant p53 expression [63]. In addition, GOF mutation-induced conforma-
tional changes in mutant p53 allow the binding of Hsp90 (heat shock protein 90) to mutant 
p53, which prevents Mdm2 binding and Mdm2-mediated degradation of mutant p53 [60]. 
It is now well established that elevated mutant p53 levels correlate with more aggressive 
tumors and poor prognosis. About 96% of high-grade serous ovarian cancer patients have 
GOF p53 mutations, which orchestrate a distinct pro-tumorigenic transcription and onco-
genic programs. Knowledge of a UPS component responsible for mutant p53 stabilization, 
which could be chemically manipulated, will be useful in HGSOC. Nonetheless, Mdm2 is a 
great therapeutic target and prognostic factor for ovarian cancer with wild-type p53, such as 
clear-cell carcinomas [64].
3.2. Cyclin E
Genomic alterations in cell-cycle regulatory genes have been reported in almost every human 
carcinoma. Cyclins are the crucial regulators of cell-cycle progression [65]. A periodic increase 
in cyclin levels and their timed interplay with cyclin-dependent kinases (CDKs) is essential 
for the proper progression of cell cycle [65]. Their levels are regulated by a combination of 
transcription and ubiquitin-mediated degradation [18, 66]. About 30% of high-grade serous 
ovarian cancer patients have amplification of the CCNE1 gene, which encodes for G1/S-
specific cyclin E. Cyclin E-CDK2 interactions commit the cell to S-phase genome duplication 
[3]. Aberrant accumulation and overabundance of cyclin E leads to premature entry of the cell 
into S-phase, resulting in chromosome instability and tumor formation [67]. Cyclin E ampli-
fication is likely to be an early event in the development of high-grade serous ovarian cancer 
[3]. This subclass of patients has no apparent defect in homologous recombination as seen 
in patients with BRCA1 and BRCA2 mutations with defect in DNA repair pathways [3]. The 
overexpression of cyclin E is an indicator of poor overall survival of ovarian cancer patients. 
Cyclin E protein levels are maintained by a multi-subunit SCF ubiquitin ligase, which medi-
ates its ubiquitination and degradation [68]. Cyclin E auto-phosphorylation after its associa-
tion with CDK2 is recognized by the SCF-associated F-box protein 7 (FBXW7), which binds to 
cyclin E and facilitates its ubiquitination and degradation [68, 69]. More than 30% of human 
cancers have a deleted FBXW7 gene located on chromosome 4q32. FBXW7 also regulates 
mTOR, Myc, and Notch1 degradation, depending upon the type of tumor [70, 71]. FBXW7 is 
known to be mutated in breast and ovarian cancer cell lines with high cyclin E levels [3]. The 
loss of cyclin E or CDK2 results in cell-cycle arrest or apoptosis in HGSOC cell lines [3], sug-
gesting cyclin E inhibition as a novel therapeutic approach in ovarian cancer patients.
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3.3. P27, a cyclin-dependent kinase inhibitor
Similar to cell-cycle regulatory proteins, cell-cycle inhibitors are frequently altered in can-
cer [72, 73]. p27Kip1 inhibits cell-cycle G1 phase by interacting with CDK2/cyclin A or CDK2/
cyclin E complexes [73, 74]. Low levels of p27Kip1 protein are associated with tumor progres-
sion and growth resulting in poor prognosis of ovarian and breast cancer patients [74–76]. 
The evaluation of subcellular localization of p27Kip1 in tissue microarray of late-stage ovar-
ian cancer patients revealed that patients with nuclear-only expression of p27Kip1 had a better 
overall survival than those with negative expression or cytoplasmic localization of the marker 
(p-value = 0.0002; n = 355) [77]. p27Kip1 level is an important prognostic marker of malignant 
transformation. Genetically altered mice with p27Kip1 haploinsufficiency are predisposed to 
cancer [78]. p27Kip1 protein levels are regulated by SCF E3 ligase-associated protein Skp2. Skp2 
binds to p27Kip1 and mediates its ubiquitination and subsequent proteasomal degradation [79, 
80]. Skp2 levels in different cancers correlate with tumor grade and inversely correlate with 
p27Kip1 levels and cancer prognosis. Skp2 levels were upregulated in ovarian cancer patients 
and were associated with advanced FIGO stage III and IV and high grade of the tumor [81]. 
Skp2 levels were also associated with downregulation of both p27 and p21 in these patients, 
suggesting an important role of Skp2- p27Kip1 pathway in ovarian cancer pathogenesis. A 
strong negative correlation between Skp2 levels and FOXO3a (r = −0.743; p < 0.05) in immuno-
histochemical analysis of ovarian cancer patients indicates that it is another potential target of 
Skp2 in ovarian cancer [82]. These findings and Skp2 overexpression or amplification in serous 
ovarian cancer characterize it as an oncogene and its inhibition a plausible approach in ovarian 
cancer management.
3.4. The epidermal growth factor receptor (also known as HER or ERBB) family
The EGFR family of receptor tyrosine kinases plays an important role in the pathogenesis 
of several cancers [83]. The four members: EGFR, HER2, HER3, and HER4 (or ERBB1–4), 
of EGFR family structurally consist of an extracellular ligand-binding domain, a single 
transmembrane-spanning region, and an intracellular tyrosine kinase domain. More than 
30 ligands have been identified that bind to the EGFR family receptors, including EGF- and 
EGF-like ligands, transforming growth factor (TGF)-α, and heregulins (HRGs) [83]. The acti-
vated EGFR receptors undergo C-terminal phosphorylation of cytoplasmic tyrosine residues 
after receptor dimerization to mediate cell regulatory signaling. E3 ubiquitin ligase CBL 
binds to EGFR receptor at specific phosphotyrosine residues and mediates its ubiquitina-
tion subsequent internalization in clatherin-coated endosomes, which then lead to lysosome-
mediated degradation of EGFR [84].
Amplifications and overexpression of various EGFR family members, including EGFR, Her2, 
and ErbB3, have been reported in epithelial ovarian cancer. Attenuated ubiquitination and 
HER2 gene amplification favor the formation of EGFR/HER2 heterodimers that recruit CBL 
to a lesser degree, thus stabilizing and recycling the receptor to cell surface [85]. BRCA1 muta-
tions are known to be associated with an increased EGFR expression in serous ovarian cancer 
patients. EGFR expression was not only increased in BRCA1 mutated cancer tissues but was 
also high in BRCA1-mutated normal tissues compared to respective control tissues. These 
Ovarian Cancer - From Pathogenesis to Treatment146
results were confirmed by knocking down BRCA1 in ovarian cancer cells [86]. However, 
inhibitors targeting this pathway have little effect on cancer cells as a single agent due to the 
presence of alternative pathways affecting the cancer phenotype, particularly the activation of 
the PI3K/Akt/mTOR and mitogen-activated protein kinases (MAPKs) pathway [83], suggest-
ing a combined use of EGFR and PI3K inhibitors in ovarian cancer [87].
4. Concluding remarks
It is now well known that UPS not only mediates protein degradation but is also involved 
in the extensive regulation of cellular functions and signaling. A large number of studies in 
various cancers have uncovered the diverse and intricate role of ubiquitin in oncogenic sig-
naling. The alterations in the genes involved in UPS support its role in cancer development 
and progression. However, the lack of information on DUBs specificity and multiple targets 
of E3s raise a question on the use of DUBs or E3s inhibitors in cancer treatment. One possible 
way forward is to characterize the cancer-specific and tissue-specific expression of DUBs as 
certain DUBs are predominantly expressed in certain tissues and cancer, suggesting the can-
cer-specific use of a DUB inhibitor. Moreover, most DUBs studied thus far appear to regulate 
a small number of targets. It is also possible that only a fraction of ubiquitinated proteins are 
regulated by a specific DUB family. Similarly, the E3s can be manipulated in cancer if their 
role is characterized in cancer-specific aberrant molecular signaling. Moreover, further char-
acterization of mutations in DUBs or E3s in cancer patients can be used for cancer screening. 
In addition, proteasomes carry a great potential in cancer treatment. Although Bortezomib 
did not show promising results against solid tumors, the advent of next-generation protea-
some inhibitors opens new possibilities. Currently, five different types of next-generation 
proteasome inhibitors are in phase I or phase IIb clinical trials. Moreover, understanding the 
regulation of proteasomal activity by altered proteasome composition may open novel ways 
to target proteasomes in cancer.
Compared to breast cancer, ovarian cancer is a rare but far more lethal cancer. It is estimated 
that 69% of all patients with ovarian carcinoma will succumb to their disease as compared 
with 19% of those with breast cancer [1]. Ovarian cancer heterogeneity is represented by sev-
eral genetic (BRCA1/2), epigenetic, and signaling (p53, CDK/p27, CCNE1) alterations, and 
various UPS components are implicated in these ovarian cancer-specific alterations. Several 
studies have established a link between UPS and ovarian cancer. However, further studies are 
needed to identify potential inhibitors for proteasome-based or E3s/DUBs-based therapies in 
ovarian cancer, which can be taken to clinical trials.
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